Aduro Biotech Inc. (NASDAQ:ADRO) fell 3.2% during trading on Tuesday . The company traded as low as $15.55 and last traded at $15.59, with a volume of 231,588 shares trading hands. The stock had previously closed at $16.10.

A number of brokerages recently commented on ADRO. FBR & Co reissued a “buy” rating and issued a $34.00 price objective (up from $30.00) on shares of Aduro Biotech in a research note on Saturday, May 14th. Canaccord Genuity reissued a “buy” rating on shares of Aduro Biotech in a research note on Tuesday, May 3rd. Zacks Investment Research lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Leerink Swann restated a “buy” rating and issued a $48.00 target price on shares of Aduro Biotech in a report on Thursday, May 5th. Finally, Roth Capital restated a “buy” rating and issued a $22.00 target price (down from $46.00) on shares of Aduro Biotech in a report on Monday, May 16th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $22.00.

The company’s market cap is $1.00 billion. The firm has a 50-day moving average of $13.79 and a 200 day moving average of $13.20.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.21. The company had revenue of $39 million for the quarter, compared to the consensus estimate of $25.24 million. The business’s revenue was up 306.3% on a year-over-year basis. Equities research analysts anticipate that Aduro Biotech Inc. will post ($1.15) earnings per share for the current year.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $15.18, for a total transaction of $379,500.00. Following the transaction, the insider now owns 12,500 shares in the company, valued at approximately $189,750. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

A hedge fund recently raised its stake in Aduro Biotech stock. Jennison Associates LLC increased its position in Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned 1.35% of Aduro Biotech worth $24,069,000 at the end of the most recent quarter.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.